SAVA - Cassava Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3400
-0.0100 (-0.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.3500
Open1.3600
Bid1.3400 x 1200
Ask1.4500 x 1100
Day's Range1.3212 - 1.3900
52 Week Range0.2200 - 2.9900
Volume120,315
Avg. Volume170,371
Market Cap23.074M
Beta (3Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-12-13
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswirelast month

    Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, its President and CEO, will present at Maxim Group’s conference on Alzheimer’s disease on Wednesday, June 26th, in New York.  Maxim’s conference for investors, titled “Alzheimer’s Disease – What’s Next? Treating Alzheimer’s in a Post-Amyloid World”, will be held at their corporate offices at 405 Lexington Ave in New York. Cassava Sciences’ presentation for this conference is now available on the Company’s website under https://www.cassavasciences.com/company-presentations.

  • GlobeNewswire2 months ago

    Cassava Sciences Announces New Website Launch

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com.  Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key focus of the Company’s research and development. Cassava Sciences expects to announce results of its Phase2a study in the second half of 2019, after patient data are analyzed.

  • GlobeNewswire3 months ago

    Cassava Sciences Reports First Quarter 2019 Financial Results

    AUSTIN, Texas, April 29, 2019 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported financial results for the first quarter ended March 31,.

  • GlobeNewswire3 months ago

    Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimer’s Disease

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease.  Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the National Institutes of Health (NIH).